NATCO Pharma Limited announced its financial results for the second quarter of Fiscal Year 2027 (Q2 FY27). The company reported a total revenue of INR 10,194 million. Key highlights include an EBITDA of INR 3,100 million with a margin of 30.4%, and Earnings Per Share (EPS) of INR 11.31. The company also detailed strategic investments and acquisitions made during the quarter, including an additional stake in Adcock Ingram Holding Limited.
NATCO Pharma Reports Q2 FY27 Financial Highlights
NATCO Pharma Limited has released its financial performance for the second quarter ending September 30, 2026 (Q2 FY27). The company reported a consolidated total revenue of INR 10,194 million for the quarter. This marks a significant period of operational and financial activity for the company.
Key Financial Performance Indicators
The company’s Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) stood at INR 3,100 million, with an EBITDA margin of 30.4%. This compares to 30.9% in the previous quarter (Q1 FY27). Profit after share of profit of associate for Q2 FY27 was reported at INR 2,026 million. Earnings Per Share (EPS) for the quarter was INR 11.31.
Segmental Performance and Revenue Breakup
In terms of segmental performance, API Revenue for Q2 FY27 was INR 613 million. The Pharmaceutical Formulation segment generated a total revenue of INR 8,141 million, comprising Domestic Formulations at INR 1,457 million and International Formulations (including profit share and subsidiaries) at INR 6,684 million. Crop Health Sciences contributed INR 610 million, and other operating & non-operating income amounted to INR 831 million.
The revenue breakup for Q2 FY27 shows International Formulations comprising 66% of the total revenue, Domestic Formulation at 14%, API at 6%, Crop Health Sciences at 6%, and Others at 8%.
Strategic Investments and Acquisitions
During the quarter, NATCO acquired an additional 13.25% stake in Adcock Ingram Holding Limited, bringing the total holdings to 49%. The profit share from its associate, Adcock Ingram Holdings Ltd, for Q2 FY27 was INR 292 million. Additionally, the company invested an additional US$ 16.7 million in eGenesis, Inc., bringing NATCO’s total investment in eGenesis to US$ 24.7 million.
Key Product Pipeline and Investments
The company highlighted its key product pipeline in the USA, featuring 29 Para IVs and over 20 FTFs (including sole and shared). Notable products include Kyprolis, Imbruvica, Ozempic, and Wegovy. NATCO also detailed its investments in NCE (New Chemical Entity) and Cell & Gene Therapy, including significant investments in eGenesis, NRC-2694, Cellogen Therapeutics, and Stero Therapeutics.
Earnings Call Details
NATCO Pharma will host an earnings call on November 13, 2026, at 4:00 PM IST to discuss the company’s operational and financial performance. The call will feature senior management, including Mr. Rajeev Nannapaneni (Vice Chairman and CEO) and Mr. Amit Parekh (Chief Financial Officer).
Source: BSE
